Woodhead Publishing Nanoparticulate Drug Delivery: Perspectives on the Transition from Laboratory to Market (Woodhead Publishing Series in Biomedicine)

Nanoparticulate drug delivery highlights and examines the transition of nanoparticulate drug delivery systems, operating at scales of billionths of a metre, from laboratory into a commercially viable sector. This has been a challenging journey, beginning in 2005 with the introduction of Abraxane, the first nanotechnology-based drug delivery product for the treatment of breast cancer, which marked the advent of nanotechnology in the pharmaceutical and healthcare industry. The book describes the need for various types of nanoparticulate drug delivery systems in different application areas, and assesses the challenges associated with their advance to society. Key Features: discusses the issues surrounding nanoparticulate products, based on personal experience of their formulation; provides an overview of new application areas, including RNA interference; outlines the pros and cons of nanoparticulate products, and discusses how these may influence their route into the commercial sector; provides information relevant to both the industrial and the academic sectors. Contents: Nanoparticulate systems as drug carriers: The need; Nanoparticles as drug carriers; Characterization techniques for nanoparticulate carriers; Nanotoxicology: Evaluating toxicity potential of drug-nanoparticles; Regulatory aspects of nanoparticulate drug delivery systems; Clinical trials and industrial aspects; Case studies: Nano-systems in the market.